by ComplianceQuest

My Dashboard Inspection Tracker FDA Guidance Templates Assessments

Sign in Get started

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

ANALYTICS

Tracker Overview Enforcement Themes

FDA ACTIONS

Form 483s Warning Letters Inspections Recalls

AUDIT READINESS

COMPANIES

Companies Facilities

Loading…

Dashboard Warning LettersWarning Letter Details

Novo Nordisk Inc. Warning Letter Details

Warning Letter

Novo Nordisk Inc.

800 Scudders Mill Road Plainsboro , NJ 08536 United States

Issue DateMarch 05, 2026

FEI NumberN/A

Violations2

CountryUnited States

Issuing Office

Center for Drug Evaluation and Research (CDER)

Product Type

Drugs

Status

Open

Subject

Postmarketing Adverse Drug Experience Reporting Requirements

Novo Nordisk Inc. FDA Warning Letter, March 5, 2026